XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUE
 9 Months Ended
Sep. 29, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE
3. REVENUE
Our revenue is generated from the sale of products and services. Product revenue consists of sales of instruments and consumables used in genetic analysis. Service and other revenue consists of revenue generated from genotyping and sequencing services, instrument service contracts, development and licensing agreements, and, prior to the Spin-Off of GRAIL on June 24, 2024, cancer detection testing services related to the GRAIL business.
Revenue by Source
Q3 2024Q3 2023
In millionsSequencingMicroarrayTotalSequencingMicroarrayTotal
Consumables$741 $66 $807 $689 $71 $760 
Instruments104 3 107 178 3 181 
Total product revenue845 69 914 867 74 941 
Service and other revenue150 16 166 162 16 178 
Total revenue$995 $85 $1,080 $1,029 $90 $1,119 
YTD 2024YTD 2023
In millionsSequencingMicroarrayTotalSequencingMicroarrayTotal
Consumables$2,160 $216 $2,376 $2,108 $219 $2,327 
Instruments330 12 342 524 13 537 
Total product revenue2,490 228 2,718 2,632 232 2,864 
Service and other revenue499 51 550 456 62 518 
Total revenue$2,989 $279 $3,268 $3,088 $294 $3,382 
Revenue by Geographic Area
Based on region of destination (in millions)Q3 2024Q3 2023YTD 2024YTD 2023
Americas$609 $663 $1,852 $1,920 
Europe291 260 859 825 
Greater China (1)
75 98 228 302 
Asia-Pacific, Middle East, and Africa (2)
105 98 329 335 
Total revenue$1,080 $1,119 $3,268 $3,382 
_____________
(1)Region includes revenue from China, Taiwan, and Hong Kong.
(2)Region includes revenue from Russia and Turkey.
Performance Obligations
We regularly enter into contracts with multiple performance obligations. These contracts are believed to be firm as of the balance sheet date. However, we may allow customers to make product substitutions as we launch new products. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters. Most performance obligations are generally satisfied within a short time frame, approximately three to six months, after the contract execution date. As of September 29, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was $688 million, of which approximately 82% is expected to be converted to revenue in the next twelve months, approximately 13% in the following twelve months, and the remainder thereafter.
Contract Assets and Liabilities
Contract assets, which consist of revenue recognized and performance obligations satisfied or partially satisfied in advance of customer billing, were $16 million and $18 million as of September 29, 2024 and December 31, 2023, respectively, and were recorded in prepaid expenses and other current assets.
Contract liabilities, which consist of deferred revenue and customer deposits, as of September 29, 2024 and December 31, 2023, were $293 million and $329 million, respectively, of which $235 million and $252 million, respectively, was short-term and recorded in accrued liabilities and the remaining long-term portions were recorded in other long-term liabilities. Revenue recorded in Q3 2024 and YTD 2024 included $48 million and $213 million, respectively, of previously deferred revenue that was included in contract liabilities as of December 31, 2023.